<DOC>
	<DOCNO>NCT02112175</DOCNO>
	<brief_summary>The purpose study compare safety efficacy Lenalidomide versus Placebo maintenance follow melphalan , prednisone velcade induction therapy newly diagnose multiple myeloma .</brief_summary>
	<brief_title>Lenalidomide v Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy NDMM</brief_title>
	<detailed_description>The plan total number evaluable subject PFS approximately 351 ( 234 lenalidomide treatment arm ; 117 placebo treatment arm ) study conduct European country . However , due significant enrollment challenge change NDMM treatment practice subject eligible transplant , recent approval Revlimid NDMM setting , DMC recommend close study enrollment . Study enrollment close 12 October 2015 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion eligible enrollment study : Related initial diagnosis prior Melphalan Prednisone Velcade ( MPV ) induction therapy 1 . Previously untreated symptomatic multiple myeloma . 2 . All 3 criterion ( Durie , 2003 ) least one Creatinine Renal insufficiency Anemia lytic Bone lesion osteoporosis criterion must meet . 3 . Measurable disease protein electrophoresis analysis . 4 . All subject must treat minimum 6 maximum 9 cycle MPV induction regimen , must achieve least Partial Response best overall response maintain Melphalan Prednisone Velcade discontinuation . If subject achieve Complete Response prior least 6 cycle , subject eligible , minimum 6 cycle must administer otherwise . 5 . Subjects must receive prior antimyeloma chemotherapy investigational agent except 69 cycle induction therapy Melphalan Prednisone Velcade . 6 . Subjects must cytogenetic ( 17 p deletion , 4 ; 14 translocation ) , β2 microglobulin serum albumin ( International Staging System ) result initial diagnosis available time screen . Related subject 7 . Must understand voluntarily sign informed consent document prior conduct study related assessments/procedures , 8 . Age ≥ 65 year : &lt; 65 year age , subject must non eligible stem cell transplantation , 9 . Eastern Cooperative Oncology Group performance status score ≤ 2 , 10 . Able adhere study visit schedule protocol requirement , 11 . Females Childbearing Potential must : 1 . Have two negative pregnancy test verify study doctor prior start study therapy . She must agree ongoing pregnancy test course study , end study therapy . This apply even subject practice true abstinence2 heterosexual contact . 2 . Either commit true abstinence heterosexual contact ( must review monthly basis ) agree use , able comply , effective contraception without interruption , 28 day prior start Investigational Product , study therapy ( include dose interruption ) , 28 day discontinuation study therapy . 12 . Male Subjects must : 1 . Practice true abstinence agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption least 28 day follow Investigational Product discontinuation , even undergone successful vasectomy . 2 . Agree donate semen Investigational Product therapy 28 day end study therapy . 13 . All subject must : 1 . Have understand study medication could potential teratogenic risk . 2 . Agree abstain donate blood take Investigational Product therapy follow discontinuation Investigational Product therapy . 3 . Agree share study medication another person . 4 . All female childbearing potential male subject must counsel pregnancy precaution risk fetal exposure . The presence follow exclude subject study enrollment : 1 . Previous treatment antimyeloma therapy require 69 cycle Melphalan Prednisone Velcade induction therapy ( include local radiotherapy , bisphosphonates , single short course steroid [ ie , less equal equivalent dexamethasone 40 mg/day 4 day ; short course steroid treatment must give within 14 day randomization ] ) . 2 . Subjects n't achieve Partial Response well get least 6 cycle Melphalan Prednisone Velcade end Melphalan Prednisone Velcade whatever overall response eligible . 3 . Prior therapy immunomodulating immunosuppressive agent , epigenetic desoxyribonucleic acid modulate agent . Subjects receive investigational agent also exclude . 4 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 5 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study 6 . Pregnant lactating female . 7 . Any following laboratory abnormality : Absolute neutrophil count &lt; 1,000/L ( 1.0 x 10*9/L ) Untransfused platelet count &lt; 50,000 cells/L ( 50 x 10*9/L ) Serum glutamic oxaloacetic transaminase/alanine aminotransferase serum glutamic pyruvic transaminase/alanine aminotransferase &gt; 3.0 x upper limit normal Serum bilirubin level &gt; 1.5 x upper limit normal 8 . Renal insufficiency ( creatinine clearance &lt; 30 mL/min CockcroftGault method ) actual creatinine clearance result , renal failure require hemodialysis peritoneal dialysis . 9 . Prior history malignancy include skin cancer , multiple myeloma . 10 . Prior history deep venous thrombosis pulmonary embolus within 3 year randomization . 11 . Subjects unable unwilling undergo antithrombotic therapy . 12 . Peripheral neuropathy &gt; Grade 2 severity accord National Cancer Institute Common Terminology Criteria Adverse Events Version 4.0 . 13 . Known Human Immunodeficiency Virus positivity active infectious hepatitis , type A , B , C. 14 . Primary amyloidosis ( immunoglobulin light chain ) myeloma complicate amyloidosis . 15 . Prior allogeneic autologous stem cell transplantation . 16 . Significant active cardiac disease within previous 6 month include : New York Heart Association class IIIV congestive heart failure Unstable angina angina require surgical medical intervention Myocardial infarction 17 . Any condition confound ability interpret data study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Revlimid</keyword>
	<keyword>MPV</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Velcade</keyword>
	<keyword>Placebo</keyword>
</DOC>